Therefore, we assessed the correlation between CEP55 expression and clinical characteristics and found that CEP55 expression was greater in high-stage tumors (Stages III and IV) than in low-stage tumors (Stages I and II) of ACC, HNSC, KICH, KIRP, KIRC, LIHC, LUAD, and LUSC, whereas CEP55 expression was lower in high-stage than low-stage COAD tumors (Figure 2D; Supplementary Figure S2A). This evidence concerns the gene CEP55 and adrenal cortex carcinoma.